IL13 and neoplasm: Combined with the above analysis, we suggest that in most cases, dupilumab has no effect on tumor progression or even prevents tumor progression by blocking the IL-4/IL-13 pathway and/or inhibiting the transformation of TAMs to the M2 phenotype.